Paul A. Friedman, M.D.

Paul A. Friedman, M.D.

DirectoratMadrigal Pharmaceuticals· In proxies 2021–2025

Pay in FY2023+77% from the year before · Madrigal Pharmaceuticals stock -20.3% the same year

Paul A. Friedman, M.D. was paid $9.6M in FY2023 (Dec), up 77%. Madrigal Pharmaceuticals stock fell 20.3% that year.

Pay$100 in the stock at the end of FY20 → $208
Pay is from the Summary Compensation Table of each Madrigal Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Madrigal PharmaceuticalsPublic company · 5 yr
    • Director2021 – Present · 5 yrStock in role +259%
  2. Prelude TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  3. Alexion Pharmaceuticals, Inc.Public company · 9 yr
    • Director2017 – Present · 9 yrNo stock prices for these years
  4. IncytePublic company · 20 yr
    • Director2001 – 2021 · 20 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?